



(51) International Patent Classification:

C07K 16/32 (2006.01) *A61K 39/00* (2006.01)
C07K 14/725 (2006.01) *A61P 35/00* (2006.01)
C07K 14/705 (2006.01)

(21) International Application Number:

PCT/US2023/065537

(22) International Filing Date:

07 April 2023 (07.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/329,287 08 April 2022 (08.04.2022) US

(71) Applicants: **FATE THERAPEUTICS, INC.** [US/US];

12278 Scripps Summit Drive, San Diego, CA 92131 (US).
ONO PHARMACEUTICAL CO., LTD. [JP/JP]; 1-5,
 Dosho-machi 2-chome, Chuo-ku, Osaka, 541-8526 (JP).

(72) Inventors: **VALAMEHR, Bahram**; 12278 Scripps Summit

Drive, San Diego, CA 92131 (US). **LEE, Tom, Tong**;
 12278 Scripps Summit Drive, San Diego, CA 92131 (US).
HOSKING, Martin; 12278 Scripps Summit Drive, San
 Diego, CA 92131 (US). **YAMAMOTO, Susumu**; c/o Ono

Pharmaceutical Co., Ltd., 1- 1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka, 618-8585 (JP). **MAEDA, Tatsuo**; c/o Ono Pharmaceutical Co., Ltd., 1- 1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka, 618-8585 (JP).

(74) Agent: **GIERING, Jeffery, C.** et al.; Greenberg Traurig, LLP, 77 West Wacker Drive, Suite 3100, Chicago, IL 606101 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING




FIG. 6

(57) Abstract: Provided are chimeric antigen receptors (CAR) specific to a selected tumor antigen. Also provided are structure designs and function profiles of provided CAR candidates.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*